

Table 1. Characteristics of the apheresis and final anti-CD19-CAR products: one from a healthy subject and two from a patient with B-CLL

	Apheresis Products			Final Products		
	Healthy Donor VR1 (%)	Patient VR2 (%)	Patient VR3 (%)	Healthy Donor VR1 (%)	Patient VR2 (%)	Patient VR3 (%)
CD3+	49.6	11.4	12.9	95.0	98.2	99.7
CD3+ CD4+	32.1	NT	6.5	38.4	NT	66.1
CD3+ CD8+	15.9	NT	5.5	43.8	31.0	31.9
CD19+	12.9	NT	80.7	0.3	NT	0.0
CD56+	8.2	0.9	1.1	0.1	NT	0.1

NT = not tested

Supplemental Table 1. Number of cells (x10e6) during the Expansion Phase of manufacture

	Healthy Donor VR1	Patient VR2	Patient VR3
Day 2	15	35	35
Day 4	13	45	39
Day 7	41	60	92
Day 9	56	126	138
Day 11	95	190	273
Day 14	146	290	484